ZA200203622B - Vaccines for mycoplasma bovis and methods of use. - Google Patents
Vaccines for mycoplasma bovis and methods of use. Download PDFInfo
- Publication number
- ZA200203622B ZA200203622B ZA200203622A ZA200203622A ZA200203622B ZA 200203622 B ZA200203622 B ZA 200203622B ZA 200203622 A ZA200203622 A ZA 200203622A ZA 200203622 A ZA200203622 A ZA 200203622A ZA 200203622 B ZA200203622 B ZA 200203622B
- Authority
- ZA
- South Africa
- Prior art keywords
- bovis
- biotype
- vaccine
- mycoplasma
- inactivated
- Prior art date
Links
- 241001138504 Mycoplasma bovis Species 0.000 title claims description 160
- 229960005486 vaccine Drugs 0.000 title claims description 96
- 238000000034 method Methods 0.000 title claims description 28
- 241001465754 Metazoa Species 0.000 claims description 52
- 241000283690 Bos taurus Species 0.000 claims description 43
- 230000002238 attenuated effect Effects 0.000 claims description 28
- 239000002671 adjuvant Substances 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 13
- 230000002163 immunogen Effects 0.000 claims description 13
- 230000001681 protective effect Effects 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 241000204003 Mycoplasmatales Species 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 22
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 244000144980 herd Species 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 244000309466 calf Species 0.000 description 15
- 241000204031 Mycoplasma Species 0.000 description 14
- 208000004396 mastitis Diseases 0.000 description 13
- 244000005700 microbiome Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 241000191276 Mycoplasma alkalescens Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000013365 dairy product Nutrition 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 229960000380 propiolactone Drugs 0.000 description 6
- 241001430197 Mollicutes Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 231100000065 noncytotoxic Toxicity 0.000 description 4
- 230000002020 noncytotoxic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000009021 pre-vaccination Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000013048 microbiological method Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000203022 Acholeplasma laidlawii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 241000711895 Bovine orthopneumovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000606831 Histophilus somni Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000202955 Mycoplasma bovigenitalium Species 0.000 description 1
- 241001148550 Mycoplasma bovirhinis Species 0.000 description 1
- 241001148551 Mycoplasma canadense Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16428699P | 1999-11-08 | 1999-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200203622B true ZA200203622B (en) | 2003-07-30 |
Family
ID=22593810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200203622A ZA200203622B (en) | 1999-11-08 | 2002-05-07 | Vaccines for mycoplasma bovis and methods of use. |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US7943153B1 (https=) |
| EP (1) | EP1229929A2 (https=) |
| JP (1) | JP2003513935A (https=) |
| AU (1) | AU782508B2 (https=) |
| BR (1) | BR0015398A (https=) |
| CA (1) | CA2390613A1 (https=) |
| IL (1) | IL149471A0 (https=) |
| MX (1) | MXPA02004627A (https=) |
| WO (1) | WO2001034189A2 (https=) |
| ZA (1) | ZA200203622B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0015398A (pt) * | 1999-11-08 | 2002-06-25 | Biomune | Vacinas para mycoplasma bovis e processos de uso |
| GB0110851D0 (en) * | 2001-05-03 | 2001-06-27 | Mini Agriculture & Fisheries | Vaccine |
| US20030147914A1 (en) * | 2001-07-02 | 2003-08-07 | Pfizer Inc. | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| CA2457514A1 (en) * | 2001-08-28 | 2003-03-06 | Pfizer Products Inc. | Mycoplasma bovis challenge model, methods for administering m.bovis and methods for inducing pneumonic lung lesions |
| EP2121721A4 (en) * | 2006-09-07 | 2010-10-06 | Boehringer Ingelheim Vetmed | GENOTYPING ON PCR BASE |
| CL2008003202A1 (es) | 2007-10-29 | 2009-11-27 | Boehringer Ingelheim Vetmedica Inc | Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. |
| EP2217271B1 (en) * | 2007-11-06 | 2016-05-04 | Zoetis Services LLC | Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine |
| EP2163239A1 (de) * | 2008-05-27 | 2010-03-17 | Qiagen GmbH | Produkte, die Biopartikel enthalten, Verfahren zu ihrer Herstellung |
| CA2729080C (en) * | 2008-07-03 | 2018-09-11 | Ricardo Rosenbusch | Cattle vaccines |
| AU2009309041B2 (en) * | 2008-10-31 | 2016-02-04 | Boehringer Ingelheim Animal Health USA Inc. | Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition |
| UY32570A (es) * | 2009-04-24 | 2010-11-30 | Boehringer Ingelheim Vetmed | Vacuna viva modificada de mycoplasma bovis mejorada |
| US9539209B2 (en) | 2009-06-04 | 2017-01-10 | National Institute Of Infectious Diseases | Vaccine for mycoplasma infection |
| CN102648003B (zh) | 2009-10-09 | 2016-01-13 | 儿童医疗中心有限公司 | 选择性裂解的全细胞疫苗 |
| WO2012041635A1 (en) * | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
| US9052315B2 (en) | 2012-05-09 | 2015-06-09 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
| US10359614B2 (en) | 2012-07-03 | 2019-07-23 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
| HUE059179T2 (hu) | 2012-09-10 | 2022-10-28 | Galenbio Inc | Vízimadárban Mycoplasma-fertõzés megelõzésére szolgáló oltóanyag |
| US9797893B2 (en) | 2013-05-09 | 2017-10-24 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
| EP4137152A1 (en) | 2015-08-14 | 2023-02-22 | Zoetis Services LLC | Mycoplasma bovis compositions |
| CN110338138B (zh) * | 2019-06-19 | 2021-04-06 | 山东省农业科学院奶牛研究中心 | 一种牛支原体感染豚鼠的动物模型构建方法及其应用 |
| CN113040094B (zh) * | 2021-03-18 | 2022-06-21 | 中国农业大学 | 一种牛支原体性小鼠乳腺炎模型的构建方法及其应用 |
| CN116751723A (zh) * | 2023-07-24 | 2023-09-15 | 吉林农业大学 | 一种牛支原体菌株及其灭活疫苗和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1188985A (en) | 1980-07-01 | 1985-06-18 | National Research Development Corporation | Production of viral antigens |
| US4425330A (en) * | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
| US4517394A (en) * | 1983-07-05 | 1985-05-14 | W. R. Grace & Co. | Preparation of nitro compounds by vapor phase nitration of carboxylic acids |
| US4981684A (en) | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| US5178860A (en) | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
| CA2057946A1 (en) * | 1990-12-20 | 1992-06-21 | Michael M. Thackeray | Electrochemical cell |
| US5316875A (en) * | 1991-07-19 | 1994-05-31 | Matsushita Electric Industrial Co., Ltd. | Secondary battery with nonaqueous electrolyte and method of manufacturing same |
| US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| US5585098A (en) | 1993-11-23 | 1996-12-17 | Ovimmune, Inc. | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants |
| CA2183684C (en) * | 1994-02-18 | 2008-07-15 | Richard D. Hansen | Inoculation of animals with dried, pelleted biological materials |
| JP3702353B2 (ja) * | 1996-05-24 | 2005-10-05 | 日本電池株式会社 | リチウム電池用正極活物質の製造方法およびリチウム電池 |
| BR0015398A (pt) * | 1999-11-08 | 2002-06-25 | Biomune | Vacinas para mycoplasma bovis e processos de uso |
| DE29921392U1 (de) * | 1999-12-06 | 2000-03-16 | Dr. Felgenträger & Co. Öko-Chem. und Pharma GmbH, 06862 Rodleben | Mykoplasma-bovis-Kombinations-Vakzine für Rinder |
| US6680143B2 (en) * | 2000-06-22 | 2004-01-20 | The University Of Chicago | Lithium metal oxide electrodes for lithium cells and batteries |
| US6677082B2 (en) * | 2000-06-22 | 2004-01-13 | The University Of Chicago | Lithium metal oxide electrodes for lithium cells and batteries |
| JP3500424B2 (ja) * | 2000-08-31 | 2004-02-23 | 独立行政法人産業技術総合研究所 | 単相リチウムフェライト系複合酸化物 |
| US6548069B2 (en) | 2001-02-03 | 2003-04-15 | Hmv Associates, Inc. | Multivalent Mycoplasma bacterin |
-
2000
- 2000-11-08 BR BR0015398-2A patent/BR0015398A/pt not_active Application Discontinuation
- 2000-11-08 IL IL14947100A patent/IL149471A0/xx unknown
- 2000-11-08 JP JP2001536186A patent/JP2003513935A/ja active Pending
- 2000-11-08 WO PCT/US2000/042000 patent/WO2001034189A2/en not_active Ceased
- 2000-11-08 US US09/708,352 patent/US7943153B1/en not_active Expired - Fee Related
- 2000-11-08 CA CA002390613A patent/CA2390613A1/en not_active Abandoned
- 2000-11-08 EP EP00989763A patent/EP1229929A2/en not_active Withdrawn
- 2000-11-08 AU AU26225/01A patent/AU782508B2/en not_active Ceased
- 2000-11-08 MX MXPA02004627A patent/MXPA02004627A/es not_active Application Discontinuation
-
2002
- 2002-05-07 ZA ZA200203622A patent/ZA200203622B/en unknown
-
2003
- 2003-12-01 US US10/726,029 patent/US7429389B2/en not_active Expired - Fee Related
-
2004
- 2004-04-14 US US10/825,391 patent/US7416734B2/en not_active Expired - Fee Related
-
2006
- 2006-07-18 US US11/489,147 patent/US20070077260A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/982,082 patent/US20090263427A1/en not_active Abandoned
- 2007-10-31 US US11/982,265 patent/US20080226671A1/en not_active Abandoned
- 2007-10-31 US US11/982,079 patent/US20090220550A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0015398A (pt) | 2002-06-25 |
| US7416734B2 (en) | 2008-08-26 |
| AU2622501A (en) | 2001-06-06 |
| WO2001034189A2 (en) | 2001-05-17 |
| EP1229929A2 (en) | 2002-08-14 |
| US20070077260A1 (en) | 2007-04-05 |
| MXPA02004627A (es) | 2004-02-18 |
| JP2003513935A (ja) | 2003-04-15 |
| US7943153B1 (en) | 2011-05-17 |
| US20080226671A1 (en) | 2008-09-18 |
| CA2390613A1 (en) | 2001-05-17 |
| AU782508B2 (en) | 2005-08-04 |
| WO2001034189A3 (en) | 2001-12-27 |
| US20050053627A1 (en) | 2005-03-10 |
| US7429389B2 (en) | 2008-09-30 |
| IL149471A0 (en) | 2002-11-10 |
| US20050118200A1 (en) | 2005-06-02 |
| US20090220550A1 (en) | 2009-09-03 |
| US20090263427A1 (en) | 2009-10-22 |
| US20080069842A9 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090263427A1 (en) | Vaccines for mycoplasma bovis and methods of use | |
| JP5074656B2 (ja) | 改良されたマイコプラズマハイオニューモニエバクテリンワクチン | |
| HUP0400434A2 (en) | One dose vaccination with mycoplasma hyopneumoniar | |
| JP5651677B2 (ja) | 各種血清型のブタ連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｓｕｉｓ）細菌から防御するためのワクチン | |
| US6585981B1 (en) | Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae | |
| US6632439B2 (en) | Fusobacterium necrophorum vaccine and method for making such vaccine | |
| WO2003000204A2 (en) | Multivalent mycoplasma bacterin | |
| AU685569B2 (en) | Pasteurella multocida toxoid vaccines | |
| US6743430B1 (en) | Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose | |
| EP1871410A2 (en) | Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines | |
| Sohier et al. | Comparison of protection against caseous lymphadenitis in sheep induced by local isolated strain of corynebacterium pseudotuberculosis by toxoid pld & toxoid pld With Bacterin Vaccine | |
| KR20120039115A (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| CA2312296C (en) | Pasteurella multocida toxoid vaccines | |
| Walker | Bacterial vaccines | |
| CA2086258C (en) | Pasteurella multocida toxoid vaccines | |
| AU2001277207A2 (en) | Temperature-sensitive live vaccine for mycoplasma hyopneumoniae | |
| HK1134900B (en) | One dose vaccination with (1) mycoplasma hyopneumoniae (/1) |